Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Dr Neal Shore (Carolina Urologic Research Center, Myrtle Beach, USA), Prof Eleni Efstathiou (Houston Methodist Cancer Center, Houston, USA), Prof Fred Saad (University of Montreal Hospital Center, Montreal, Canada) and Prof Andrew Armstrong (Duke University, Durham, USA) discuss the PARPi data from ESMO 2021 and its role in mono/combination therapies.
Initially, they discuss where and when do we use PARPis and the combination studies for PARPis.
Prof Saad, Prof Efstathiou and Prof Armstrong talk about their personal clinical experiences and how these can inform the use of combinations and single agents.
Dr Shore mentions the latest developments in standards of care.
Prof Armstrong and Prof Efstathiou further discuss how to decide which treatments are the best for each stage of disease and the role of biomarkers/testing.
They conclude by giving their final comments regarding what the future looks like for prostate cancer treatment.
| Combination therapies with PARPis for mCRPC | |
| PARPis' potential in non-DDR mutation landscape | |
| Increasing PARPness | |
| Potential biomarkers that can enhance therapy | |
| HRQoL for patients with mCRPC | |
| Genomic profiling for mCRPC | |
| Biomarkers for adverse events and toxicity | |
| BAT combined with olaparib for mCRPC | |
| Closing comments |
This programme has been supported by an unrestricted educational grant from AstraZeneca.
